Global Targeted Drug ALK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
According to this study, the global Targeted Drug ALK Inhibitors for NSCLC market size will reach US$ million by 2031.
Targeted Drug ALK Inhibitors for NSCLC are a new class of drugs that have been developed to specifically target abnormalities in the ALK gene that occur in some cases of non-small cell lung cancer (NSCLC). These drugs work by blocking the activity of the ALK protein, which may help to slow or stop the growth of cancer cells. There are several different types of ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and others.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug ALK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug ALK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug ALK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug ALK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug ALK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug ALK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug ALK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug ALK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug ALK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug ALK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug ALK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
Targeted Drug ALK Inhibitors for NSCLC are a new class of drugs that have been developed to specifically target abnormalities in the ALK gene that occur in some cases of non-small cell lung cancer (NSCLC). These drugs work by blocking the activity of the ALK protein, which may help to slow or stop the growth of cancer cells. There are several different types of ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and others.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug ALK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug ALK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug ALK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug ALK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug ALK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug ALK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug ALK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug ALK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug ALK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug ALK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug ALK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Crizotinib
- Ceritinib
- Alectinib
- Brigatinib
- Lorlatinib
- Others
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Novartis
- Chugai Pharmaceutical (Hoffmann-La Roche group)
- ARIAD Pharmaceuticals (Takeda)
- Genvio Pharma Limited
- Beacon Pharma Limited
- Drug International Limted
- Incepta Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug ALK Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug ALK Inhibitors for NSCLC Segment by Type
2.2.1 Crizotinib
2.2.2 Ceritinib
2.2.3 Alectinib
2.2.4 Brigatinib
2.2.5 Lorlatinib
2.2.6 Others
2.3 Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug ALK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG ALK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG ALK INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG ALK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug ALK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug ALK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug ALK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug ALK Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Information
11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Main Business Overview
11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Latest Developments
11.4 ARIAD Pharmaceuticals (Takeda)
11.4.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.4.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.4.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.5 Genvio Pharma Limited
11.5.1 Genvio Pharma Limited Company Information
11.5.2 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Genvio Pharma Limited Main Business Overview
11.5.5 Genvio Pharma Limited Latest Developments
11.6 Beacon Pharma Limited
11.6.1 Beacon Pharma Limited Company Information
11.6.2 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Beacon Pharma Limited Main Business Overview
11.6.5 Beacon Pharma Limited Latest Developments
11.7 Drug International Limted
11.7.1 Drug International Limted Company Information
11.7.2 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Drug International Limted Main Business Overview
11.7.5 Drug International Limted Latest Developments
11.8 Incepta Pharmaceuticals
11.8.1 Incepta Pharmaceuticals Company Information
11.8.2 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Incepta Pharmaceuticals Main Business Overview
11.8.5 Incepta Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug ALK Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug ALK Inhibitors for NSCLC Segment by Type
2.2.1 Crizotinib
2.2.2 Ceritinib
2.2.3 Alectinib
2.2.4 Brigatinib
2.2.5 Lorlatinib
2.2.6 Others
2.3 Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug ALK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG ALK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG ALK INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG ALK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug ALK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug ALK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug ALK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug ALK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug ALK Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug ALK Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug ALK Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Information
11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Main Business Overview
11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Latest Developments
11.4 ARIAD Pharmaceuticals (Takeda)
11.4.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.4.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.4.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.5 Genvio Pharma Limited
11.5.1 Genvio Pharma Limited Company Information
11.5.2 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Genvio Pharma Limited Main Business Overview
11.5.5 Genvio Pharma Limited Latest Developments
11.6 Beacon Pharma Limited
11.6.1 Beacon Pharma Limited Company Information
11.6.2 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Beacon Pharma Limited Main Business Overview
11.6.5 Beacon Pharma Limited Latest Developments
11.7 Drug International Limted
11.7.1 Drug International Limted Company Information
11.7.2 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Drug International Limted Main Business Overview
11.7.5 Drug International Limted Latest Developments
11.8 Incepta Pharmaceuticals
11.8.1 Incepta Pharmaceuticals Company Information
11.8.2 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Offered
11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Incepta Pharmaceuticals Main Business Overview
11.8.5 Incepta Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug ALK Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Crizotinib
Table 4. Major Players of Ceritinib
Table 5. Major Players of Alectinib
Table 6. Major Players of Brigatinib
Table 7. Major Players of Lorlatinib
Table 8. Major Players of Others
Table 9. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 12. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 14. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 15. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 16. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 17. Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 18. Targeted Drug ALK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 22. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 23. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 24. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 25. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 26. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 27. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 28. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 29. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 30. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 31. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 32. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 33. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 34. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 35. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 36. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 37. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 39. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 41. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Targeted Drug ALK Inhibitors for NSCLC
Table 43. Key Market Challenges & Risks of Targeted Drug ALK Inhibitors for NSCLC
Table 44. Key Industry Trends of Targeted Drug ALK Inhibitors for NSCLC
Table 45. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 46. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 47. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 48. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 49. Pfizer Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 50. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 51. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 52. Pfizer Main Business
Table 53. Pfizer Latest Developments
Table 54. Novartis Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 55. Novartis Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 56. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 57. Novartis Main Business
Table 58. Novartis Latest Developments
Table 59. Chugai Pharmaceutical (Hoffmann-La Roche group) Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 61. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 62. Chugai Pharmaceutical (Hoffmann-La Roche group) Main Business
Table 63. Chugai Pharmaceutical (Hoffmann-La Roche group) Latest Developments
Table 64. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 65. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 66. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 67. ARIAD Pharmaceuticals (Takeda) Main Business
Table 68. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 69. Genvio Pharma Limited Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 70. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 71. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 72. Genvio Pharma Limited Main Business
Table 73. Genvio Pharma Limited Latest Developments
Table 74. Beacon Pharma Limited Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 75. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 76. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 77. Beacon Pharma Limited Main Business
Table 78. Beacon Pharma Limited Latest Developments
Table 79. Drug International Limted Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 80. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 81. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 82. Drug International Limted Main Business
Table 83. Drug International Limted Latest Developments
Table 84. Incepta Pharmaceuticals Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 85. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 86. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 87. Incepta Pharmaceuticals Main Business
Table 88. Incepta Pharmaceuticals Latest Developments
Table 1. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug ALK Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Crizotinib
Table 4. Major Players of Ceritinib
Table 5. Major Players of Alectinib
Table 6. Major Players of Brigatinib
Table 7. Major Players of Lorlatinib
Table 8. Major Players of Others
Table 9. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 12. Targeted Drug ALK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 14. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 15. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 16. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 17. Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 18. Targeted Drug ALK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 22. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 23. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 24. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 25. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 26. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 27. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 28. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 29. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 30. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 31. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 32. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 33. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 34. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 35. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 36. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 37. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 39. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 41. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Targeted Drug ALK Inhibitors for NSCLC
Table 43. Key Market Challenges & Risks of Targeted Drug ALK Inhibitors for NSCLC
Table 44. Key Industry Trends of Targeted Drug ALK Inhibitors for NSCLC
Table 45. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 46. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 47. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 48. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 49. Pfizer Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 50. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 51. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 52. Pfizer Main Business
Table 53. Pfizer Latest Developments
Table 54. Novartis Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 55. Novartis Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 56. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 57. Novartis Main Business
Table 58. Novartis Latest Developments
Table 59. Chugai Pharmaceutical (Hoffmann-La Roche group) Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 61. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 62. Chugai Pharmaceutical (Hoffmann-La Roche group) Main Business
Table 63. Chugai Pharmaceutical (Hoffmann-La Roche group) Latest Developments
Table 64. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 65. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 66. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 67. ARIAD Pharmaceuticals (Takeda) Main Business
Table 68. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 69. Genvio Pharma Limited Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 70. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 71. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 72. Genvio Pharma Limited Main Business
Table 73. Genvio Pharma Limited Latest Developments
Table 74. Beacon Pharma Limited Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 75. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 76. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 77. Beacon Pharma Limited Main Business
Table 78. Beacon Pharma Limited Latest Developments
Table 79. Drug International Limted Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 80. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 81. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 82. Drug International Limted Main Business
Table 83. Drug International Limted Latest Developments
Table 84. Incepta Pharmaceuticals Details, Company Type, Targeted Drug ALK Inhibitors for NSCLC Area Served and Its Competitors
Table 85. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Offered
Table 86. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 87. Incepta Pharmaceuticals Main Business
Table 88. Incepta Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug ALK Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug ALK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug ALK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug ALK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug ALK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug ALK Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 1. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug ALK Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug ALK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug ALK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug ALK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug ALK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug ALK Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug ALK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug ALK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
More Publications
Global Targeted Drug HER2 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
78 pages
Global Targeted Drug ROS1 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
70 pages
Global Targeted Drug BRAF Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
74 pages
Global Targeted Drug MEK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
76 pages
Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
76 pages
